Statements (247)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:academic_programs |
gptkb:Dr._Thomas_H._Schaefer
gptkb:Dr._Anja_H._Schmidt |
| gptkbp:acquired |
gptkb:Merial
|
| gptkbp:acquisition |
gptkb:Actelion
gptkb:Merial multiple companies in the pharmaceutical sector |
| gptkbp:advertising |
gptkb:Dr._Thomas_H._Schaefer
gptkb:Dr._Thomas_H._Huber gptkb:Dr._Michael_Schaefer gptkb:Dr._Klaus_H._Schaefer |
| gptkbp:advocacy |
engages with patient advocacy groups
|
| gptkbp:aims_to |
reduce COVID-19 severity
|
| gptkbp:annual_report |
published yearly
publishes annual financial reports |
| gptkbp:awards |
recognized for innovation
recognized for sustainability efforts received numerous industry awards receives various innovation awards |
| gptkbp:biopharmaceuticals |
develops biopharmaceutical products
|
| gptkbp:business_model |
gptkb:Dr._Thomas_H._Schaefer
|
| gptkbp:ceo |
gptkb:Hubertus_von_Baumbach
|
| gptkbp:clinical_research_partnerships |
forms clinical research partnerships with institutions
|
| gptkbp:clinical_trial |
conducts numerous clinical trials annually
ongoing research conducts numerous clinical trials invests heavily in clinical research advances clinical development processes |
| gptkbp:collaborated_with |
various research institutions
|
| gptkbp:collaborates_with |
government agencies
academic institutions |
| gptkbp:collaborations |
academic institutions
various biotech companies engages in research collaborations with universities |
| gptkbp:community_engagement |
healthcare access programs
|
| gptkbp:community_health |
contributes to global health initiatives
|
| gptkbp:conducts_research_on |
gptkb:Dr._Clive_Wood
various leading scientists |
| gptkbp:covid-19_impact |
Boehringer Ingelheim's COVID-19 treatment
|
| gptkbp:cultural_diversity |
promotes diversity in the workplace
|
| gptkbp:dedicated_to |
patient safety
|
| gptkbp:developed_by |
antiviral therapies
|
| gptkbp:development |
over 50,000
|
| gptkbp:digital_transformation |
gptkb:Dr._Andreas_H._Weber
embraces digital technologies |
| gptkbp:divisions |
animal health
human pharmaceuticals |
| gptkbp:drug_discovery |
focuses on drug discovery processes
|
| gptkbp:drug_safety |
ensures drug safety through rigorous testing.
|
| gptkbp:employees |
approximately 50,000
approximately 52,000 |
| gptkbp:employs |
over 50,000 people
|
| gptkbp:focus |
research and development
|
| gptkbp:focuses_on |
animal health
oncology chronic diseases cardiovascular diseases infectious diseases respiratory diseases human pharmaceuticals |
| gptkbp:founded |
1885
|
| gptkbp:founder |
gptkb:Albert_Boehringer
|
| gptkbp:funding |
provides research funding to various projects
|
| gptkbp:global_presence |
healthcare
over 150 countries |
| gptkbp:governance |
gptkb:Dr._Michael_Schaefer
gptkb:Dr._Clive_Wood gptkb:Dr._Claudia_H._Meyer |
| gptkbp:has_a_focus_on |
gptkb:biotechnology
sustainable practices therapeutic areas global health issues patient needs innovation in medicine |
| gptkbp:has_a_pipeline_of |
new drugs
|
| gptkbp:has_a_presence_in |
gptkb:Africa
gptkb:Europe gptkb:Asia gptkb:Latin_America gptkb:North_America |
| gptkbp:has_authority_over |
gptkb:Dr._Jürgen_H._Müller
|
| gptkbp:has_culture |
emphasizes employee well-being
|
| gptkbp:has_developed |
COVID-19 therapies
|
| gptkbp:has_history |
innovation
pharmaceutical development |
| gptkbp:has_mission |
improve health
|
| gptkbp:has_partnerships_with |
healthcare organizations
|
| gptkbp:has_received |
numerous awards
|
| gptkbp:has_research_center |
multiple research centers worldwide
|
| gptkbp:head |
gptkb:Dr._Stefan_H._Schmitt
|
| gptkbp:head_of_animal_health |
gptkb:Dr._Hubertus_von_Baumbach
|
| gptkbp:head_of_clinical_operations |
gptkb:Dr._Thomas_H._Huber
|
| gptkbp:head_of_corporate_audit |
gptkb:Dr._Clive_Wood
|
| gptkbp:head_of_corporate_legal |
gptkb:Dr._Clive_Wood
|
| gptkbp:head_of_corporate_risk_management |
gptkb:Dr._Thomas_H._Schaefer
|
| gptkbp:head_of_corporate_training |
gptkb:Dr._Michael_Schaefer
|
| gptkbp:head_of_human_pharmaceuticals |
gptkb:Dr._Michael_Schaefer
|
| gptkbp:head_of_market_access |
gptkb:Dr._Andreas_H._Weber
|
| gptkbp:head_of_medical_affairs |
gptkb:Dr._Michael_H._Schaefer
|
| gptkbp:head_of_pharmacovigilance |
gptkb:Dr._Claudia_H._Meyer
|
| gptkbp:head_of_state |
gptkb:Dr._Thomas_H._Schaefer
gptkb:Dr._Michael_Schaefer gptkb:Dr._Clive_Wood gptkb:Dr._Thomas_H._Müller gptkb:Dr._Anja_H._Schmidt gptkb:Dr._Christine_H._Huber gptkb:Dr._Rainer_H._Müller |
| gptkbp:headquartered_in |
gptkb:Germany
gptkb:Ingelheim_am_Rhein |
| gptkbp:headquarters |
gptkb:Ingelheim_am_Rhein
gptkb:Ingelheim,_Germany Ingelheim am Rhein, Germany |
| gptkbp:healthcare |
develops innovative healthcare solutions
drives healthcare innovation globally improves healthcare access in underserved regions provides resources for healthcare professionals |
| https://www.w3.org/2000/01/rdf-schema#label |
Boehringer Ingelheim
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:innovation |
focuses on innovative therapies
|
| gptkbp:invention |
holds thousands of patents
numerous pharmaceutical patents numerous patents in drug development |
| gptkbp:investment |
gptkb:Dr._Michael_Schaefer
gptkb:Dr._Klaus_H._Becker research and development COVID-19 research invests in research and development |
| gptkbp:is_a_member_of |
various industry associations
|
| gptkbp:is_committed_to |
diversity and inclusion
innovation public health sustainability corporate social responsibility research funding ethical practices community health |
| gptkbp:is_engaged_in |
patient advocacy
|
| gptkbp:is_focused_on |
gptkb:biotechnology
|
| gptkbp:is_involved_in |
community engagement
clinical trials public health initiatives global health initiatives healthcare solutions vaccine development |
| gptkbp:is_known_for |
high-quality products
collaborative research innovative therapies high standards of quality |
| gptkbp:is_part_of |
the pharmaceutical industry
|
| gptkbp:is_privately_held |
gptkb:Company
|
| gptkbp:is_recognized_for |
scientific excellence
high-quality products its contributions to science |
| gptkbp:leadership |
animal health products
pharmaceutical research led by a board of directors human health products |
| gptkbp:logistics |
gptkb:Dr._Peter_H._Becker
|
| gptkbp:market |
works on market access strategies
global pharmaceutical market animal health market |
| gptkbp:market_position |
one of the largest privately-owned pharmaceutical companies
|
| gptkbp:marketed_as |
various well-known drugs
|
| gptkbp:marketing_strategy |
COVID-19 response
|
| gptkbp:offers |
generic drugs
biopharmaceuticals |
| gptkbp:operates_in |
gptkb:pharmaceuticals
over 150 countries more than 150 countries |
| gptkbp:partnership |
biotech companies
various universities various academic institutions |
| gptkbp:partnerships |
collaborates with healthcare organizations
various biotech companies |
| gptkbp:philanthropy |
supports education initiatives
supports health-related charities supports disaster relief efforts supports various health initiatives |
| gptkbp:portfolio_company |
therapeutics
|
| gptkbp:produces |
vaccines
therapeutics |
| gptkbp:products |
animal health products
vaccines biopharmaceuticals prescription medications prescription medicines |
| gptkbp:provides_guidance_on |
contributes to clinical guidelines
|
| gptkbp:public_relations |
gptkb:Dr._Thomas_H._Schaefer
gptkb:Dr._Michael_Schaefer gptkb:Dr._Clive_Wood gptkb:Dr._Julia_H._Fischer gptkb:Dr._Michael_H._Schneider various executives |
| gptkbp:publications |
publishes scientific research
|
| gptkbp:regulatory_compliance |
gptkb:Dr._Thomas_H._Schaefer
gptkb:Dr._Michael_Schaefer gptkb:Dr._Andreas_Neumann gptkb:Dr._Peter_H._Becker adheres to global regulatory standards |
| gptkbp:research |
oncology
cardiovascular diseases respiratory diseases metabolic diseases |
| gptkbp:research_areas |
gptkb:diabetes
neurology oncology cardiovascular diseases respiratory diseases metabolic diseases |
| gptkbp:research_focus |
animal health
biopharmaceuticals human pharmaceuticals |
| gptkbp:revenue |
private company
approximately €19 billion family-owned over €19 billion |
| gptkbp:risk_management |
gptkb:Dr._Julia_H._Fischer
|
| gptkbp:safety |
prioritizes patient safety in drug development
|
| gptkbp:social_responsibility |
gptkb:healthcare_access
gptkb:Dr._Thomas_H._Schaefer community engagement education initiatives committed to CSR initiatives |
| gptkbp:strategy |
gptkb:Dr._Thomas_H._Schaefer
gptkb:Dr._Klaus_H._Becker focuses on global health challenges |
| gptkbp:subsidiaries |
gptkb:Boehringer_Ingelheim_Pharmaceuticals
gptkb:Boehringer_Ingelheim_Animal_Health |
| gptkbp:supply_chain |
gptkb:Dr._Michael_Schaefer
gptkb:Dr._Thomas_H._Müller gptkb:Dr._Rainer_H._Müller manages a global supply chain works on supply chain sustainability initiatives |
| gptkbp:sustainability_initiatives |
social responsibility
environmental responsibility economic responsibility |
| gptkbp:training |
provides extensive training programs
|
| gptkbp:treatment |
aims to improve clinical outcomes for patients
|
| gptkbp:type_of_business |
gptkb:Dr._Michael_H._Schneider
|
| gptkbp:type_of_care |
advocates for patient-centered care approaches
|
| gptkbp:user_engagement |
fosters employee engagement programs
|
| gptkbp:veterinary_medicine |
offers veterinary medicines
|
| gptkbp:vision |
healthcare innovation
|
| gptkbp:was_a_pioneer_in |
pharmaceutical development
|
| gptkbp:website |
www.boehringer-ingelheim.com
|
| gptkbp:bfsParent |
gptkb:biotechnology
|
| gptkbp:bfsLayer |
3
|